DBV TECHNOLOGIES reports a Return on Equity (ROE) of -109.63%.

What is DBVT's dividend yield?

DBV TECHNOLOGIES offers a dividend yield of 0.00%.

What is DBVT's Quality Score?

Our AI rates DBVT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy DBVT?

Our AI Timing Score for DBVT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does DBVT belong to?

DBV TECHNOLOGIES is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

DBVT (NASDAQ) Stock Analysis | DBV TECHNOLOGIES

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

DBVT AI Analysis Summary

Our AI summary for DBVT: DBV TECHNOLOGIES (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -109.63%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

DBVT

DBV TECHNOLOGIES

US:NASDAQ STOCK Healthcare >> Biotechnology News 88

USD 13.50

-0.31 (-2.24%) Day Change

Watchlist Portfolio Compare Chart

0.09

D/E

-109.6%

ROE

-78.8%

ROA

0.00%

Div Yield

DBV TECHNOLOGIES
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 13.50 Price -0.31 (-2.24%) Day Change	NEWS SCORE: 88

DBVT, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	88
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	13.50
PBV / Sector	5.10 / 5.20
Earning Per Share	-2.90

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	4.35 M GREAT
Average 1W Daily Value	5.91 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	-2,292.70 / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-78.78 / 27.02
ROA Average (%) / Sector	-78.73 / -368.17
ROA Change Average (%) / Sector	74.79 / 5,404.12 GREAT
ROE (%) / Sector	-109.63 / 3.47
ROE Average (%) / Sector	-142.66 / 6.51
ROE Change Average (%) / Sector	163.00 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:42
Symbol	DBVT
Name	DBV TECHNOLOGIES
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	59.19 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	817.38 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: BAtiment IRO, Châtillon, France, 92320

Phone: 33 1 55 42 78 78

Website: https://www.dbv-technologies.com

Employees: 170

Sector: Healthcare >> Biotechnology

Description: DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.